Back Pain News and Research

Latest Back Pain News and Research

Inadequate car seat support may trigger back pain

Inadequate car seat support may be responsible for triggering back pain, reports Edmunds.com, the premier online resource for automotive information. And while there are improvised ways to ease and prevent back discomfort - like purchasing an inflatable pillow or moldable seat supports - most new cars now offer technically advanced lumbar support adjustments.

10 Nov 2011

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR or Stalevo, in patients with advanced Parkinson's disease.

9 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

APF launches new online educational module on safe use of CAM

The American Pain Foundation (APF) announced the launch of a new online educational module focusing on safe use of complementary and alternative medicine (CAM) as part of its PainSAFE initiative.

5 Nov 2011

Acorda third quarter GAAP net income increases to $18.9 million

Acorda Therapeutics, Inc. today announced its financial results for the third quarter ended September 30, 2011.

4 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

Regular Yoga eases chronic back pain: Study

A new study found that those with chronic back pain might benefit from regular yoga. Three months of weekly yoga classes eased back pain more than the usual course of care — an informative back pain booklet said researchers. Even a year later, patients with chronic back pain who had participated in yoga classes reported less pain than those who hadn't been assigned the classes.

1 Nov 2011

Obama gets clean bill of health

President Barack Obama is in excellent health and tobacco free, his doctor said Monday in the results of the president’s second physical exam since taking office.

1 Nov 2011

Spinal USA to introduce two new solutions at NASS meeting

Spinal USA, LLC announced today that it will introduce two new additions to the company's portfolio of spinal treatment solutions at this year's meeting of the North American Spine Society (NASS) in Chicago, IL, November 1-5.

29 Oct 2011

Bacterin reports results of two-year study for OsteoSponge

Bacterin International Holdings, Inc., a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, reported results of a two-year study for OsteoSponge.

27 Oct 2011

Yoga for low back pain as effective as stretching exercises: Study

Study shows that weekly yoga classes eased pain and improved functioning in some people with chronic lower back pain. However the effects of yoga were not much different from usual stretching exercises.

25 Oct 2011

CompCare to distribute innovative lumbar traction DDS belt in the U.S., Canada and Puerto Rico

Comprehensive Care Corporation, which provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the U.S., today announced that it has acquired exclusive distribution rights to an innovative patented product aimed directly at reducing depression in individuals resulting from chronic back pain.

24 Oct 2011

Health costs continue upward trend

Market Watch reports that an index tracking health care costs rose for the fourth time in a row. Meanwhile, McClatchy reports that disability benefits are on a financially unsustainable path. Finally, NPR offers advice for handling health expenses during one's golden years.

22 Oct 2011

Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis

On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.

22 Oct 2011

Watson receives FDA approval for Androderm lower-dose formulations

Watson Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved its Androderm (testosterone transdermal system) 2 mg and 4 mg formulation.

21 Oct 2011

Co-occurrence of medical and psychiatric disease is likely to affect QoL

This review provides evidence of a substantially reduced psychosocial and physical quality of life in medically ill patients with comorbid mental disorders. This patient-reported outcome highlights the importance of recognizing and treating comorbid mental disorders in the medically ill.

7 Oct 2011

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.

1 Oct 2011

Heavy smoking linked with chronic musculoskeletal pain in women

Kentucky women who smoke heavily may experience more chronic musculoskeletal pain, suggests a new study led by University of Kentucky researchers.

29 Sep 2011

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.

27 Sep 2011

Back Pain News and Research

Latest Back Pain News and Research

Inadequate car seat support may trigger back pain

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott announces results from HUMIRA Phase 3 study on axSpA

APF launches new online educational module on safe use of CAM

Acorda third quarter GAAP net income increases to $18.9 million

Takeda receives FDA approval for VELCADE sNDA to treat MM

Regular Yoga eases chronic back pain: Study

Obama gets clean bill of health

Spinal USA to introduce two new solutions at NASS meeting

Bacterin reports results of two-year study for OsteoSponge

Yoga for low back pain as effective as stretching exercises: Study

CompCare to distribute innovative lumbar traction DDS belt in the U.S., Canada and Puerto Rico

Health costs continue upward trend

Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis

Watson receives FDA approval for Androderm lower-dose formulations

Co-occurrence of medical and psychiatric disease is likely to affect QoL

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

Heavy smoking linked with chronic musculoskeletal pain in women

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Back Pain News and Research

Latest Back Pain News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in